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ECONOMIC EVALUATION OF PROPHYLACTIC PEGFILGRASTIM AND
FILGRASTIM IN PATIENTS WITH MYELOABLATIVE CHEMOTHERAPY TO AVOID
NEUTROPENIA IN THE IMSS (MEXICAN INSTITUTE OF SOCIAL SECURITY)
Nambo-Lucio M
CMN Siglo XXI, Mexico City, Mexico, Mexico
OBJECTIVES: To assess whether prophylactic use of pegfilgastrim offers better
results in terms of health and expense associated with the incidence of febrile
neutropenia (FN) associated with myelosuppressive chemotherapy compared to
filgrastim in the IMSS METHODS: The measure of effectiveness was considered by
the incidence of NF in patients receiving myeloablative chemotherapy (Qt) and
received prophylaxis. According to literature, the prophylactic use of pegfilgrastim
reduced by 90% the incidence of FN and the prophylactic use of filgrastim reduces
by 39%. We constructed a decision tree, which considered the costs of treatment
and complications, including, costs of drugs, consultations, laboratory studies,
hospitalization and procedures. The incidence of FN is 20% when is used Qt.
RESULTS: If used as a prophylactic filgrastim, average cost of prophylactic treat-
ment over the complications of FN would be US$1982. However, if used as prophy-
lactic pegfilgrastim, based on their efficiency, the cost would be US$1421. If we use
as a prophylactic pegfilgrastim we will have savings of 28% compared with using
filgrastim. Following the trend of consumption of filgrastim in IMSS published by
the Federal Institute of Access to Public Information (IFAI) and assuming that 30%
of this consumption was used for prophylaxis for patients who received Qt, then
we can estimate that the number of prophylaxis given was about 15,000 cycles in
2009. This represents average savings of treatment (including complications of NF)
of 10 million USD, however if they had been treated with pegfilgrastim savings had
been for 18 million USD or 8 million USD more savings (86%) that using filgrastim
as prophylaxis. CONCLUSIONS: The prophylactic use of pegfilgatrim reduces costs
of care for cancer patients that are in Qt in the IMSS and provides a benefit to
patients.
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OBJECTIVES: In clinical studies, prophylactic HPV vaccines have demonstrated
high efficacy in the prevention of HPV infections, cervical intraepithelial neoplasia
(CIN) and genital warts. In Germany, routine HPV vaccination is recommended for
females aged 12 to 17 years. No transmission model reflecting the German health-
care setting which evaluates the cost-effectiveness of both the bivalent and quad-
rivalent HPV vaccines has been published yet. Hence, the objective of this study
was to determine the long-term impact of both available vaccines in addition to the
existing cervical cancer screening programme in Germany. METHODS: A mathe-
matical model simulating the transmission dynamics and the natural history of
HPV infection was developed. The age-structured model takes account of the oc-
currence of CIN, cervical cancer and genital warts and was calibrated using German
data on HPV prevalence and cancer statistics. Epidemiological and economic pa-
rameter estimates were obtained from published literature and supplemented by
expert interviews. The base-case analysis was conducted from a third-party payer
perspective and assumed a vaccination coverage of 50%, 10 years of sustained
vaccine protection followed by a period of waning immunity, costs of €474 for the
initial immunisation series and a 3% discount rate on future costs and health
effects. RESULTS: Compared with current screening practice, vaccination of 12-
year-old girls prevented additional 97,822 cervical cancer cases and 23,462 deaths
over a time horizon of 100 years. Under base-case assumptions, the discounted
ICERs were €57,413 per life-year gained and €37,198 per QALY gained for the biva-
lent vaccine, and €36,700 per life-year gained and €15,229 per QALY gained for the
quadrivalent vaccine. CONCLUSIONS: Considering the commonly accepted
threshold of €50,000 per QALY gained, routine HPV-vaccination of 12-year-old girls
is likely to be cost-effective in Germany. Additional protection against genital warts
in females and males by the quadrivalent vaccine improves the cost-effectiveness
ratio substantially.
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COST-EFFECTIVENESS OF DASATINIB VERSUS HIGH-DOSE IMATINIB AND
NILOTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA RESISTANT TO
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OBJECTIVES: To assess the cost-effectiveness of dasatinib 100 mg/day vs. imatinib
600 mg/day, imatinib 800 mg/day and versus nilotinib 800 mg/day in patients with
chronic myeloid leukaemia (CML) in the chronic phase of the disease, resistant to
prior therapy with imatinib 400 mg/day from the perspective of the Portuguese
National Health Service (NHS). METHODS: A cost-utility Markov model was devel-
oped by BMS for NICE appraisal and has been adapted to the Portuguese treatment
practice. Four health states were considered, three represented CML phases
(chronic, accelerate and blast) and the death state with one-month cycles. The
model was populated with efficacy data from clinical trials, resource utilization by
expert opinion, published quality of life data for CML laypersons in the UK and unit
prices from official 2010 price lists. A life-long, NHS perspective was used and
deterministic results were determined. A deterministic sensitivity analysis was
performed to test the robustness of the results. RESULTS: The results showed that
chronic phase CML patients resistant to standard dose imatinib gain on average
2.72 life-years, or 2.38 quality adjusted life-years, when treated with dasatinib 100
mg/day compared with imatinib 600 mg/day or compared to imatinib 800 mg/day
and on average 0.53 life-years, or 0.47 quality adjusted life-years compared to ni-
lotinib 800 mg/day. The incremental cost per quality adjusted life year gained
(QALY) amounts to €39,941 when dasatinib 100 mg/day is compared with imatinib
600 mg/day, and to €14,470 when compared to imatinib 800 mg/day and to €29,422
when compared to nilotinib during a lifetime period. CONCLUSIONS: The results
indicate that dasatinib is a cost-effective option in CML patients resistant to stan-
dard-dose imatinib in Portugal in comparison with high-dose imatinib and nilo-
tinib.
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A COST–UTILITY ANALYSIS OF DEGARELIX IN THE TREATMENT OF ADVANCED
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OBJECTIVES: Degarelix is the first gonadotrophin-releasing hormone (GnRH) an-
tagonist to be launched in the UK for first-line treatment of advanced prostate
cancer. The aim of this evaluation was to predict long-term clinical and economic
outcomes from treatment with degarelix compared to treatment with goserelin,
standard current practice, from the perspective of NHS Scotland.METHODS: Anal-
yses were conducted using a 20 year semi-Markov (cohort health-state transition)
cost-utility model which was recently submitted to and accepted by the Scottish
Medical Consortium (SMC). The model considers two patient groups – the inten-
tion-to-treat population (ITT) of patients with hormone-responsive prostate cancer
in whom treatment with androgen-deprivation therapy is indicated and who
would be prescribed a LHRH agonist and a high-risk population with a baseline PSA
level 20ng/ml. Probabilistic and deterministic sensitivity analyses were con-
ducted to assess uncertainty in the model. RESULTS: The key benefit of treatment
with degarelix comes from keeping patients in the first-line treatment state for
longer, incurring less time and costs in the later more costly and lower utility
non-hormonal therapy state. At NHS list-price degarelix is estimated to dominate
treatment with goserelin within both populations with a saving of £271 and QALY
gain of 0.46 in the ITT population. Probabilistic sensitivity analyses show that de-
garelix is likely to be cost-effective (at a willingness-to-pay of £500 per QALY) in
100% of cases. CONCLUSIONS: The economic analysis shows that degarelix not
only provides a better patient outcome but is also less costly than goserelin over a
lifetime of treatment. It is rare for a new treatment to predict dominance over
existing therapies – only 18% of SMC submissions up to 2011 have predicted dom-
inance. In addition degarelix shows a large gain in quality of life (almost half a year
in full health) even when a conservative assumption of no increase in survival is
applied.
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OBJECTIVES: MM is the second most common haematological malignancy. With
the recent introduction of new agents, survival has greatly improved. This study
aimed to assess the cost-effectiveness of bortezomib (BOR) vs. dexamethasone
(DEX) as second-line treatment of RRMM. Lenalidomide in combination with dexa-
methasone (LENDEX) was also considered in a secondary analysis.METHODS:An
area under the curve decision-analytic model was developed, containing three
health states: “pre-progression”, “post-progression” and “dead”. Survival analyses
of the APEX trial (BOR vs. DEX) were used to estimate the transition probabilities by
line of treatment. As 71% of patients randomised to DEX crossed over to BOR, the
hazard ratios (HR) were adjusted for crossovers (progression-free survival [PFS]:
0.56; overall survival [OS]: 0.59). HRs for LENDEX vs. DEX (PFS: 0.35; OS: 0.71) were
retrieved from the MM-09/10 trials (not adjusted for 47.6% cross-over or line of
treatment). Treatment schedule, compliance rate and adverse events (AEs) rates
were retrieved from the above clinical trials, while utility weights were retrieved
from the published literature. The model runs over patients’ lifetime, and discount
rate of 3.5% was applied to costs and QALYs and assumptions around level of vial
sharing for bortezomib were investigated. RESULTS: BOR was associated with an
incremental effectiveness of 1.56 life years gained (LYG) and 0.86 QALYs per patient
compared to DEX, while LENDEX was found to be less effective (-0.64 LYG, -0.28
QALYs) than BOR. Scenario analyses showed BOR is cost-effective in most cases
when compared to DEX, while LENDEX was dominated by BOR. The results were
sensitive to treatment effect on survival. CONCLUSIONS: The model suggests that
BOR is a cost-effective option for treating RRMM in the UK.
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OBJECTIVES: Three formulations of leuprolide, an established LH-RH agonist are
used in the management of advanced prostate cancer. In order to inform clinical
practice, the economic impact of the different formulations and dosing schedules
were evaluated for Austria, Belgium, Czech Republic, Hungary, Italy, Latvia, The
Netherlands, Poland and Portugal.METHODS:Database searches identified 10 clin-
ical trials of leuprolide 1-monthly (1M), 3-monthly (3M) and 6-monthly (6M) with
Atrigel®, requiring 6, 4 and 2 hospital treatment visits respectively. Due to reported
comparable efficacy, safety and adherence, cost-minimisation analysis was con-
ducted. Costs of the product, specialist consultations and diagnostics (converted to
2010 euros) were considered during up to 12 months follow-up. The perspective
was that of public payers. RESULTS: The review showed that with the use of leu-
prolide 1M, 3M and 6M the respective percentage of patients achieving testosterone
suppression of 50ng/dl was 93.3%, 98.3% and 97.3% (p0.05). However, 6M was
the least cost treatment option, with average total annual costs from 788€ (Poland)
to 1839€ (Portugal). The 3M option was 2.5% (Hungary) to 37.6% (Belgium) higher
than 6M cost; while 1M formulation had the highest cost: 15.6% and 151.6% more
than 6M for those countries, respectively. The 3M option was 11.2% to 45.3% less
expensive than 1M. The cost drivers were the frequency of visits for injection and
monitoring. The study showed that up to 50% additional visits could be funded
with the savings resulting from switching eligible patients from 1M and 3M to 6M.
Results were robust in one-way sensitivity analyses, as well as probabilistic sensi-
tivity analysis. CONCLUSIONS: Leuprolide acetate with Atrigel® 1M, 3M and 6M
formulations offer comparable efficacy and safety. However, driven by the fre-
quency of visits, the 6-monthly formulation offers the greatest cost-savings for
prostate cancer patients in the European countries studied.
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THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT
COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF
CAPECITABINE  OXALIPLATIN (XELOX) VS. IV 5-FU  FA  OXALIPLATIN
(FOLFOX)
Garside J, McNamara S, Millar D
Roche Products Limited, Welwyn Garden City, UK
OBJECTIVES: XELOX is the most utilised therapy for aCC in the UK. The aim of this
analysis was to assess and compare the population net health benefit (pNHB) of all
patients with aCC switching from the FOLFOX regimen to XELOX, from a UK Na-
tional Health Service (NHS) perspective. METHODS: An indirect comparison of the
NO16968 (XELOX) and MOSAIC (FOLFOX-4) trials was undertaken (where both reg-
imens were compared to i.v. 5-FU plus FA) showing XELOX to be non-inferior. A cost
minimisation approach was therefore taken. Drug costs were based on UK list
prices taken from the British National Formulary (BNF 61), and additional costs
such as administration costs, adverse event costs and pharmacy costs were taken
from NHS reference costs, the literature and previous technology appraisals. A
£20,000/QALY assumed displacement threshold was utilised to estimate the pNHB
provided. Uncertainty was explored via one-way sensitivity analyses. RESULTS:
Replacing FOLFOX-6 and FOLFOX-4 with XELOX saved £6490 and £9778 per patient
respectively, of which £2434 and £1534 came from drug acquisition costs. Over 60%
of the total savings were realised from reductions in the frequency of pharmacy use
and administration resource use. The savings realised from full implementation of
the XELOX regimen could be used by the NHS to generate more than 1000 QALYs
over the next 5 years. The costs of AEs were similar across all three regimens.
XELOX achieved savings of £3,400 per patient even when all parameters in the
sensitivity analysis were simultaneously set to the worse case scenarios.
CONCLUSIONS: XELOX has been demonstrated to be cost-effective and signifi-
cantly cost-saving versus FOLFOX-4 and FOLFOX-6 in aCC from an NHS perspec-
tive. Full conversion of all aCC patients to XELOX could offer the NHS substantial
financial savings and a significant pNHB of over 1000 QALYs over a 5 year period.
PCN104
COST MINIMIZATION ANALYSIS (CMA) OF CAPECITABINE/CISPLATIN (XP) VS.
5-FU/CISPLATIN (FP) REGIMENS IN ADVANCED GASTRIC CANCER (AGC)
TREATMENT IN THE ROMANIAN SETTING
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OBJECTIVES: The objective was to compare the first-line therapy costs of
capecitabinecisplatin(XP) and 5-FUcisplatin (FP) in patients with AGC in the
Romanian health care system. METHODS: Due to similar efficacy as shown in the
study ML 17 032 (Kang et al.) a cost minimization analysis was performed (CMA).
Direct costs of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and unit costs in Roma-
nian hospitals from payer perspective (National Health Insurance House). Adverse
event (AE) profiles were used to calculate costs of treating AEs. An expert panel
estimated typical treatment patterns and costs of treating major AEs. RESULTS: XP
arm patients received 5.2 cycles vs. 4.6 cycles in FP arm. The substitution of oral
capecitabine for infusional 5-FU reduced the number of hospital clinic visits by 17.6
(22.8 for FP versus 5.2 for XP). Drug costs were estimated to be ROL 5,230 greater in
the XP arm, but drug administration costs were ROL 5,904 lower, yielding a net cost
saving of ROL 674 per patient (1Euro4,2 ROL). Adverse event profiles were almost
similar: associated costs to treat AEs were less than ROL 270 per patient and were
lower in the XP arm by ROL 67. Total incremental cost was - ROL 741 in favor of XP
regimen. CONCLUSIONS: Oral capecitabine treatment is a cost-saving regimen for
AGC from Romanian public payer’s perspective.
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OBJECTIVES: Metastatic colorectal cancer (mCRC) accounts for a substantial eco-
nomic and clinical burden worldwide. The aim of the present study was to conduct
an economic evaluation in Greece comparing panitumumab with cetuximab in the
monotherapy treatment of patients with non-mutated (wild-type) KRAS, epider-
mal growth factor receptor (EGFR)-expressing mCRC. METHODS: Based on litera-
ture search, panitumumab and cetuximab are assumed to have similar efficacy,
hence a cost-minimization analysis was carried out from the third-payer-party
(Sickness Fund) and the National Health Service (NHS) perspective. A probabilistic
model was constructed to estimate the resource utilization and costs associated
with the management of patients receiving either therapy. Due to known differ-
ences in various settings regarding drug use, two type of analysis were undertaken:
one reporting “cost per mg” and another reporting “cost per vial”. Treatment cost
accounted for administration of second line chemotherapy, laboratory and bio-
chemical examinations and for hospitalization due to toxicity. Data on resource
utilization were collected from two oncology units in Greece and prices refer to
2011. Non parametric bootstrapping was employed to deal with uncertainty and to
estimate variability measures. RESULTS: From a third-payer-party perspective, it
was found that the mean 20-week total cost per patient for panitumumab and
cetuximab in the “per mg analysis” was €16,349 (95%CI: 16,036.7-16,637.8) and
€18,242 (95%CI: 17,902.4-18,597.9), respectively. The corresponding mean total
costs obtained in “per vial analysis” was €18,808 (95%CI: 18,437.7-19,161.7) and
€19,701 (95%CI: 19,358.6-20,053.1), respectively. From the NHS perspective, while
the mean total costs per patient were higher than for third party payers, versus
cetuximab, panitumumab was still associated with a 12.40% and 17.7% cost reduc-
tion in per-vial and per-mg analysis, respectively. CONCLUSIONS: In the Greek
NHS and Sickness Fund setting, panitimumab may represent a cost-saving option
compared with cetuximab in the management of patients with non-mutated (wild-
type) KRAS, epidermal growth factor receptor (EGFR)-expressing mCRC.
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CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS
FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III
COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD
COSTS IN THE NETHERLANDS
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OBJECTIVES: Recent publications have demonstrated equal efficacy of capecit-
abine and fluorouracil/leucovorin in combination with oxaliplatin in the adjuvant
treatment of stage III colon cancer. It is stated that CAPOX and FOLFOX can be used
interchangeably. METHODS: A cost-minimization analysis was performed using a
Markov model, a two-year time horizon and a hospital perspective. Assuming
equal efficacy of CAPOX and FOLFOX, transition probabilities were based on the
MOSAIC trial (Andre et al., 2004 and 2009). Dutch real-world population-based
treatment and follow-up cost were calculated using a representative sample of 102
patients treated with oxaliplatin for stage III colon cancer in 19 hospitals in the The
Netherlands. Resource use was collected from the first administration of adjuvant
chemotherapy until disease progression (or end of follow-up). Costs of drug acqui-
sition, drug administration, patient monitoring, and adverse events were consid-
ered and reported in euro 2009. RESULTS: In Dutch practice, the median time on
adjuvant treatment was 24 weeks for both CAPOX and FOLFOX, as recommended in
the guidelines. Mean total costs were € 19,373 for CAPOX and € 31,324 for FOLFOX,
resulting in a significant overall cost savings of € 11,951 for CAPOX compared with
FOLFOX. Main savings resulted from administration costs (€ 8,460), due to in-
creased hospital admissions in the FOLFOX treatment as the administration of
fluorouracil involves a 48-hour continuous infusion. Other savings were obtained
from acquisition costs (€ 2181) and costs of managing adverse events (€ 1427).
Monitoring costs were comparable in CAPOX and FOLFOX. Probabilistic sensitivity
analysis confirmed the robustness of the results. CONCLUSIONS: CAPOX is cost-
saving in comparison with FOLFOX for the adjuvant treatment of stage III colon
cancer in a real-world setting in the The Netherlands. Considering the high inci-
dence of colon cancer in the The Netherlands, substantial overall savings can be
realized by routine use of CAPOX in this indication.
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POTENTIAL BENEFITS OF INTRODUCING A COMPANION DIAGNOSTIC IN
ADVANCED NON-SMALL CELL LUNG CANCER
Zaim R, Gaultney J, Redekop W, Uyl-de Groot C
Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: Gefitinib is a promising first-line treatment option in advanced non-
small cell lung cancer (NSCLC) patients with positive epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) mutations. However, some patients with s`ensi-
tive´ EGFR-TK mutations and primary resistance do not respond to gefitinib
treatment. The objective of this early health technology assessment was to quan-
tify the potential health gain and cost consequences that would result with the
introduction of a companion diagnostic prior to first-line treatment of advanced
NSCLC patients with positive EGFR-TK mutations.METHODS:A Markov model was
designed to compare a companion diagnostic strategy (gefitinib or gemicitabine-
carboplatin) versus treating all patients with gefitinib (gefitinib for all). Model in-
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